PRINCETON, New Jersey, USA / TOKYO, Japan / CAMBRIDGE, Massachusetts, USA, April 28, 2026
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics have announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for zipalertinib, an investigational next-generation EGFR tyrosine kinase inhibitor for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The NDA acceptance marks a significant regulatory milestone, with a Prescription Drug User Fee Act (PDUFA) target date set for February 27, 2027, positioning zipalertinib as a potential new treatment option for patients with limited therapeutic alternatives. The application is supported by robust clinical evidence demonstrating clinically meaningful and durable responses in heavily pretreated patient populations, highlighting the drug’s potential to address a critical unmet need in oncology.
Phase 2b Trial Demonstrates Strong Clinical Efficacy
The NDA submission is based on results from the Phase 2b REZILIENT1 clinical trial, which evaluated zipalertinib monotherapy in patients with NSCLC harboring EGFR exon 20 insertion mutations who had previously received treatment. The study met its primary endpoint, demonstrating a confirmed objective response rate (ORR) of 35%, with a median duration of response (mDOR) of 8.8 months, indicating sustained clinical benefit. In patients treated after prior platinum-based chemotherapy, ORR increased to 40%, reinforcing the therapy’s efficacy in a difficult-to-treat population.
Additional subgroup analyses showed meaningful responses even in patients with prior targeted therapy exposure and those with brain metastases, underscoring the drug’s broad clinical applicability. The safety profile was consistent with previously reported data, with most adverse events being manageable and predominantly low-grade, supporting continued regulatory evaluation.
Targeted Therapy Addresses EGFR Mutation-Driven Cancer
Advertisement
Zipalertinib is an oral small-molecule inhibitor specifically designed to target EGFR exon 20 insertion mutations, a subset of genetic alterations found in approximately 4% of NSCLC cases globally. These mutations are associated with poor prognosis and limited treatment options, making them a critical focus of targeted oncology research. Unlike earlier-generation therapies, zipalertinib is engineered to selectively inhibit mutant EGFR while sparing wild-type receptors, potentially reducing off-target effects and improving tolerability.
The therapy has previously received Breakthrough Therapy Designation from the FDA, reflecting its potential to provide substantial improvement over existing treatments. This targeted approach aligns with the growing emphasis on precision medicine and biomarker-driven drug development in oncology.
Regulatory Progress and Oncology Pipeline Advancement
The acceptance of the NDA represents a pivotal step in advancing zipalertinib toward potential approval and commercialization. From a cGxP perspective, this milestone reflects the successful integration of Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Manufacturing Practice (GMP) standards, ensuring that the therapy meets rigorous requirements for safety, efficacy, and quality. The collaboration between Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics highlights the importance of global partnerships in accelerating drug development and regulatory progress.
NSCLC remains one of the most common and deadly forms of cancer worldwide, with EGFR mutations present in a significant proportion of patients. The development of therapies targeting specific genetic subtypes, such as exon 20 insertions, represents a major advancement in improving patient outcomes and expanding treatment options. With ongoing regulatory review and continued clinical research, zipalertinib has the potential to become a key addition to the evolving landscape of targeted cancer therapies, offering new hope for patients facing limited therapeutic choices.
Source: Taiho Oncology press release
